πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 32 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11865179

Progesterone formulations having a desirable PK profile

Compass Therapeutics LLC Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11135154

Medroxyprogesterone acetate injectable compositions and methods of use

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11033626

Progesterone formulations having a desirable pk profile

Compass Therapeutics LLC Β· Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10942183

Methods of detecting progesterone receptor and of detecting an expression level

Regents of the University of Minnesota Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10639375

Progesterone formulations

Compass Therapeutics LLC Β· Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10471148

Progesterone formulations having a desirable PK profile

Compass Therapeutics LLC Β· Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10052386

Progesterone formulations

Compass Therapeutics LLC Β· Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8663681

Oral dosage forms comprising progesterone and methods of making and using the same

TEVA WOMEN'S HEALTH, INC. Β· Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8580293

Monolithic intravaginal rings comprising progesterone and methods of making and uses there

TEVA WOMEN'S HEALTH, INC. Β· Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8003629

21-substituted progesterone derivatives as new antiprogestational agents

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 23 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7759330

21-substituted progesterone derivatives as new antiprogestational agents

The United States of America, as represented by the Department of Health and Human Services Β· Granted Tue Jul 20 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7723300

Regulators of the non-genomic action of progesterone and methods of use

UNIVERSITY OF CONNECTICUT Β· Granted Tue May 25 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 20 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7696246

Bicyclic androgen and progesterone receptor modulator compounds and methods

Ligand Pharmaceuticals Incorporated Β· Granted Tue Apr 13 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 08 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7163946

5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone

Ligand Pharmaceuticals Incorporated Β· Granted Tue Jan 16 2007 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 11 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7087591

21-substituted progesterone derivatives as new antiprogestational agents

The United States of America, as represented by the Department of Health and Human Services Β· Granted Tue Aug 08 2006 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 03 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7084151

5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-Ζ’]quinolines as select

Ligand Pharmaceuticals Incorporated Β· Granted Tue Aug 01 2006 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 27 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7081457

Cyclothiocarbamate derivatives as progesterone receptor modulators

Ligand Pharmaceuticals Incorporated Β· Granted Tue Jul 25 2006 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7071205

5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor

Ligand Pharmaceuticals Incorporated Β· Granted Tue Jul 04 2006 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 6964973

Bicyclic androgen and progesterone receptor modulator compounds and methods

Ligand Pharmaceuticals Incorporated Β· Granted Tue Nov 15 2005 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

expired patent

US 6861415

21-substituted progesterone derivatives as new antiprogestational agents

The United States of America, as represented by the Department of Health and Human Services Β· Granted Tue Mar 01 2005 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

expired patent

US 6759408

Combination regimens using progesterone receptor modulators

Ligand Pharmaceuticals Incorporated Β· Granted Tue Jul 06 2004 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

expired patent

US 6713478

Cyclocarbamate derivatives as progesterone receptor modulators

Ligand Pharmaceuticals Incorporated Β· Granted Tue Mar 30 2004 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

expired patent

US 6693103

1,2,3,4-tetrahydro-2-thioxo-quinolinyl and 1,2,3,4-tetrahydro-2-oxo-quinolinyl derivatives

Ligand Pharmaceuticals Incorporated Β· Granted Tue Feb 17 2004 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

expired patent

US 6566358

Cyclocarbamate derivatives as progesterone receptor modulators

Ligand Pharmaceuticals Incorporated Β· Granted Tue May 20 2003 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

expired